The Evolution of HTA in Emerging Markets Health-Care ... - TREE

More documents

Recommendations

Info

OHE Consulting Report for PhRMA 5 January 2011 References Augustovski, A., Iglesias, C., Manca, A., Drummound, M., Rubinstein, A. and Garcia Marti, S. (2009) Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics. 27(11), 919-‐929. Banta, D. and Almeida, R. (2009) The development of health technology assessment in Brazil. International Journal of Technology Assessment in Health Care. 25(Suppl 1), 255-‐259. Battista, R.N. and Hodge, M.J. (2009) The “natural” history of health technology assessment. International Journal of Technology Assessment in Health Care. 25(Suppl.1), 281-‐284. Bureau of National Health Insurance. (2010) NHI New Drug Listing and Pricing Principles. 22 January. Byrkjeflot, H. and Neby, S. (2008) The end of the decentralised model of healthcare governance. Journal of Health Organization and Management. 22(4), 331-‐349. Chalkidou, K., Levine, R. and Dillon, A. (2010) Helping poorer countries make locally informed decisions. British Medical Journal. 241, 3651. Chen, C.L., Chen, L. and Yang, W.C. (2008) The influences of Taiwan's generic grouping price policy on drug prices and expenditures: Evidence from analysing the consumption of the three most-‐used classes of cardiovascular drugs. BMC Public Health. 8, 118. Chen, H.F., Lee, C.H. and Chang, R.E. (2010) Workload of attending physicians at an academic center in Taiwan. Journal of the Chinese Medical Association. 73(8), 425-‐430. Chen, L. C., Schafheutle, E.I. and Noyce, P. R. (2009) The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan. Research in Social and Administrative Pharmacy. 5(3), 211-‐224. Cheng, L. J. and Wang, J. D. (2006) Is cost-‐effectiveness analysis necessary for national health insurance? Journal of the Formosa Medical Association. 105(12), 1031-‐ 1035. Cheng, S.H., Chen, C.C.and Chang, W.L. (2009) Hospital response to a global budget program under universal health insurance in Taiwan. Health Policy. 92(2-‐3), 158-‐164. Cheng, T.M. (2003) Taiwan's new national health insurance program: Genesis and experience so far. Health Affairs (Millwood). 22(3), 61-‐76. Cheng, T-‐S. (2009) Lessons from Taiwan’s universal national health insurance: A conversation with Taiwan’s health minister Ching-‐Chuan Yeh. Health Affairs. 28(4), 1035-‐1044. Chen, Y., Banta, D. and Tang, Z. (2009) Health technology assessment development in China. International Journal of Technology Assessment in Health Care. 25(suppl.1), 202-‐209. 114
OHE Consulting Report for PhRMA 5 January 2011 Danzon, P., Towse, A. and Mulcahy, A. (2011) Setting cost-‐effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Affairs. 30(8), 1529-‐1538. Doherty, J., Kamae, I., Lee, K.K.C., Li, H., Li, S-‐C., Liu, G.G., Tarn, Y-‐H. and Yang, B-‐M. (2004) What is next for pharmacoeconomics and outcomes research in Asia? Value in Health. 7(2), 118-‐132. Dos Santos, N.R. (2008) Public healthcare policy in Brazil: Crossroads and choices. Cien Saude Colet. 13(Suppl.2), 2009-‐2018. Drummond, M., Jönsson, B., Rutten, F. and Stargardt, T. (2010) Reimbursement of pharmaceuticals: Reference pricing versus health technology assessment. European Journal of Health Economics. 12(3), 263-‐271. Drummond, M., Schwartz, J., Jönsson, B., Luce, B., Neumann, P., Siebert, U. and Sullivan, S. (2008) Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Assessment in Health Care. 24(3), 244-‐258. EFPIA. (2005) The use of health technology assessments (HTA) to evaluate medicines. Key Principles. Brussels: European Federation of Pharmaceutical Industries and Associations. Eggleston, K. and Hsieh, C-‐R. (2004) Healthcare payment incentives: A comparative analysis of reforms in Taiwan, South Korea and China. Applied Health Economics and Health Policy. 3(1), 47-‐56. Elias, P.E.M. and Cohn, A. (2003) Health reform in Brazil: Lessons to consider. American Journal of Public Health. 93(1), 44-‐48. EUnetHTA. (2008) EUnetHTA handbook on HTA capacity building. European Network for Health Technology Assessment. Work package 8. Fernandes, E., Pires, H.M., Ignacio, A.A.V. and Sampaio, L.M.D. (2007) An analysis of the supplementary health sector in Brazil. Health Policy. 81, 242-‐257. Garrido, M.V., Gerhardus, A., Rottingen, J-‐A. and Busse, R. (2010) Developing health technology assessment to address health care system needs. Health Policy. 94(3), 196-‐202. Gerschman, S. (2008) Compared supplementary healthcare policies in the context of public health systems: European Union and Brazil. Cien Saude Colet. 13(5), 1441-‐1451. Gottret, P. and Schieber, G. (2006) Health financing revisited: A practitioner’s guide. Washington, DC: The World Bank. Hailey, D. and Juszwishin, D. (2006) Managing external risks to health technology assessment programs. International Journal of Technology Assessment in Health Care. 22(4), 429-‐435. Han, Q., Chen, L., Evans, T. And Horton, R. (2008) China and global health. The Lancet. 372, 1439-‐ 1441. 115
Page 1 and 2:
Consulting Report 1 The Evolution
Page 3 and 4:
OHE Consulting Report for PhRMA 5 J
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64: OHE Consulting Report for PhRMA 5 J
Page 113: OHE Consulting Report for PhRMA 5 J
Page 119: OHE Consulting Report for PhRMA 5 J
show all

The Evolution of HTA in Emerging Markets Health-Care ... - TREE

Create successful ePaper yourself

Delete template?

Save as template?